HUTCHMED (HCM) Competitors $13.52 -0.29 (-2.10%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$13.52 0.00 (0.00%) As of 01/31/2025 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends HCM vs. ROIV, ASND, BPMC, BBIO, RVMD, LNTH, LEGN, ELAN, CYTK, and NUVLShould you be buying HUTCHMED stock or one of its competitors? The main competitors of HUTCHMED include Roivant Sciences (ROIV), Ascendis Pharma A/S (ASND), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Revolution Medicines (RVMD), Lantheus (LNTH), Legend Biotech (LEGN), Elanco Animal Health (ELAN), Cytokinetics (CYTK), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry. HUTCHMED vs. Roivant Sciences Ascendis Pharma A/S Blueprint Medicines BridgeBio Pharma Revolution Medicines Lantheus Legend Biotech Elanco Animal Health Cytokinetics Nuvalent HUTCHMED (NASDAQ:HCM) and Roivant Sciences (NASDAQ:ROIV) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, community ranking, media sentiment and earnings. Which has more volatility & risk, HCM or ROIV? HUTCHMED has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500. Is HCM or ROIV more profitable? Roivant Sciences has a net margin of 3,827.42% compared to HUTCHMED's net margin of 0.00%. HUTCHMED's return on equity of 0.00% beat Roivant Sciences' return on equity.Company Net Margins Return on Equity Return on Assets HUTCHMEDN/A N/A N/A Roivant Sciences 3,827.42%-14.65%-13.19% Do insiders & institutionals believe in HCM or ROIV? 8.8% of HUTCHMED shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 3.6% of HUTCHMED shares are owned by insiders. Comparatively, 7.9% of Roivant Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has preferable earnings & valuation, HCM or ROIV? Roivant Sciences has lower revenue, but higher earnings than HUTCHMED. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHUTCHMED$838M2.81$100.78MN/AN/ARoivant Sciences$124.79M64.93$4.35B$5.651.97 Does the MarketBeat Community favor HCM or ROIV? HUTCHMED received 263 more outperform votes than Roivant Sciences when rated by MarketBeat users. However, 77.61% of users gave Roivant Sciences an outperform vote while only 66.32% of users gave HUTCHMED an outperform vote. CompanyUnderperformOutperformHUTCHMEDOutperform Votes31566.32% Underperform Votes16033.68% Roivant SciencesOutperform Votes5277.61% Underperform Votes1522.39% Do analysts prefer HCM or ROIV? HUTCHMED presently has a consensus target price of $19.00, indicating a potential upside of 40.53%. Roivant Sciences has a consensus target price of $17.93, indicating a potential upside of 61.08%. Given Roivant Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Roivant Sciences is more favorable than HUTCHMED.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HUTCHMED 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Roivant Sciences 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the media prefer HCM or ROIV? In the previous week, Roivant Sciences had 3 more articles in the media than HUTCHMED. MarketBeat recorded 7 mentions for Roivant Sciences and 4 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 1.36 beat Roivant Sciences' score of 0.71 indicating that HUTCHMED is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HUTCHMED 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Roivant Sciences 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryRoivant Sciences beats HUTCHMED on 12 of the 17 factors compared between the two stocks. Get HUTCHMED News Delivered to You Automatically Sign up to receive the latest news and ratings for HCM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HCM vs. The Competition Export to ExcelMetricHUTCHMEDPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.38B$6.88B$5.58B$9.12BDividend YieldN/A2.90%5.31%3.99%P/E RatioN/A4.5158.9914.21Price / Sales2.81320.231,258.0383.19Price / Cash21.8173.5045.9637.70Price / Book3.175.275.124.71Net Income$100.78M$136.98M$111.17M$224.24M7 Day Performance-0.29%-0.59%2.37%-0.17%1 Month Performance-6.18%0.18%3.19%0.60%1 Year Performance4.56%7.68%24.69%20.43% HUTCHMED Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HCMHUTCHMED3.3878 of 5 stars$13.52-2.1%$19.00+40.5%+8.2%$2.38B$838M0.001,988Short Interest ↓Positive NewsROIVRoivant Sciences3.0968 of 5 stars$11.15-0.2%$17.93+60.9%+11.3%$8.11B$124.79M1.97860Analyst UpgradeASNDAscendis Pharma A/S3.4336 of 5 stars$126.51-1.3%$192.07+51.8%+0.6%$7.71B$288.08M-15.72640Upcoming EarningsAnalyst ForecastShort Interest ↓BPMCBlueprint Medicines0.9434 of 5 stars$113.91-0.9%$123.56+8.5%+41.5%$7.23B$249.38M-53.95640Short Interest ↑BBIOBridgeBio Pharma4.0242 of 5 stars$36.64-2.5%$48.08+31.2%-0.2%$6.92B$9.30M-15.20400Insider TradeShort Interest ↑News CoverageRVMDRevolution Medicines4.4555 of 5 stars$40.73-0.6%$66.25+62.6%+54.8%$6.85B$11.58M-11.35250LNTHLantheus4.5369 of 5 stars$98.28+0.8%$131.86+34.2%+78.1%$6.83B$1.30B16.34700Short Interest ↑News CoverageLEGNLegend Biotech3.2093 of 5 stars$36.61-0.8%$79.50+117.2%-30.8%$6.69B$285.14M-38.541,800Short Interest ↓ELANElanco Animal Health4.3179 of 5 stars$12.07-0.1%$16.43+36.1%-18.4%$5.97B$4.42B30.179,300Analyst ForecastNews CoverageCYTKCytokinetics3.9289 of 5 stars$49.92-1.6%$82.79+65.8%-36.7%$5.90B$7.53M-9.30250NUVLNuvalent2.4308 of 5 stars$82.47+0.3%$112.36+36.3%+14.2%$5.84BN/A-23.7040Insider TradePositive News Related Companies and Tools Related Companies ROIV Alternatives ASND Alternatives BPMC Alternatives BBIO Alternatives RVMD Alternatives LNTH Alternatives LEGN Alternatives ELAN Alternatives CYTK Alternatives NUVL Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:HCM) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HUTCHMED (China) Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share HUTCHMED With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
